These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12906339)

  • 21. Preparation and evaluation of a sustained-release formulation of nifedipine HPMC tablets.
    Yan G; Li H; Zhang R; Ding D
    Drug Dev Ind Pharm; 2000 Jun; 26(6):681-6. PubMed ID: 10826117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food.
    Abrahamsson B; Alpsten M; Bake B; Jonsson UE; Eriksson-Lepkowska M; Larsson A
    J Control Release; 1998 Mar; 52(3):301-10. PubMed ID: 9743450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of controlled release osmotic pump tablet of glipizide solid dispersion.
    Patel GC; Asodaria KV; Patel HP; Shah DR
    Curr Drug Deliv; 2014; 11(6):817-27. PubMed ID: 23859357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice.
    Lin YK; Ho HO
    J Control Release; 2003 Apr; 89(1):57-69. PubMed ID: 12695063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and characterization of osmotic pump capsules containing polyoxyethylene and pH modifier to control the release of nifedipine.
    Yu J; Meng X; Dong X; Han M; Li G; Chen Y; Liu Y; Hu L
    Eur J Pharm Biopharm; 2021 Jun; 163():102-108. PubMed ID: 33819628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
    Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
    Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preparation of atenolol monolithic osmotic pump tablets].
    Liu LX; Che BJ; Xu Q
    Yao Xue Xue Bao; 2006 May; 41(5):457-60. PubMed ID: 16848324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical development of solid dispersion based osmotic drug delivery system for nifedipine.
    Kanagale P; Patel V; Venkatesan N; Jain M; Patel P; Misra A
    Curr Drug Deliv; 2008 Oct; 5(4):306-11. PubMed ID: 18855601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and
    Li N; Fan L; Wu B; Dai G; Jiang C; Guo Y; Wang D
    Drug Dev Ind Pharm; 2019 Jul; 45(7):1079-1088. PubMed ID: 30909753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nifedipine gastrointestinal therapeutic system.
    Swanson DR; Barclay BL; Wong PS; Theeuwes F
    Am J Med; 1987 Dec; 83(6B):3-9. PubMed ID: 3503595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The delivery mechanism of micro-porous osmotic pump tablets].
    Zhao XL; Li Q; Gong XF; Li SM
    Yao Xue Xue Bao; 2007 Feb; 42(2):226-30. PubMed ID: 17518057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of nifedipine derived from a new retard tablet formulation.
    Avgerinos A; Gorrod JW
    Eur J Drug Metab Pharmacokinet; 1990; 15(4):273-8. PubMed ID: 2088764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation, Optimization, and In vivo Evaluation of Gastroretentive Drug Delivery System of Nifedipine for the Treatment of Preeclampsia.
    Karemore MN; Avari JG
    AAPS PharmSciTech; 2019 May; 20(5):200. PubMed ID: 31127399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative human pharmacokinetic studies of 20 mg nifedipine-containing Cordaflex and Adalat film coated retared tablets].
    Klebovich I; Horvai G; Grézal G; Baloghné NK; Horváth V; Kocsi E; Balogh J; Cseh A; Farsang C
    Acta Pharm Hung; 1996 Jan; 66(1):29-39. PubMed ID: 8714363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
    Makhija SN; Vavia PR
    J Control Release; 2003 Apr; 89(1):5-18. PubMed ID: 12695059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.
    Chung M; Reitberg DP; Gaffney M; Singleton W
    Am J Med; 1987 Dec; 83(6B):10-4. PubMed ID: 3503594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet.
    Qin C; He W; Zhu C; Wu M; Jin Z; Zhang Q; Wang G; Yin L
    Int J Pharm; 2014 May; 466(1-2):276-85. PubMed ID: 24607209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery of prazosin hydrochloride from osmotic pump system prepared by coating the core tablet with an indentation.
    Liu L; Wang J; Zhu S
    Drug Deliv; 2007 Apr; 14(4):219-24. PubMed ID: 17497354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous delivery of Nifedipine and Metoprolol tartarate using sandwiched osmotic pump tablet system.
    Kumaravelrajan R; Narayanan N; Suba V; Bhaskar K
    Int J Pharm; 2010 Oct; 399(1-2):60-70. PubMed ID: 20696225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
    Grundy JS; Foster RT
    Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.